Health / Weight Loss

Wave Life Sciences' RNA Obesity Shot Shows Promising Results

Wave Life Sciences (Nasdaq: WVE) has announced positive interim data from its Phase 1 INLIGHT trial of WVE-007 (INHBE), an investigational RNA medicine for treating obesity. The single-dose study demonstrated significant improvements in bod...

Dec 08, 2025 14:02 Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss